Abstract
Purpose
Calprotectin (heterodimer of calgranulin A and B) has been previously studied as a candidate stool marker for detecting colorectal cancer. We assessed the clinical usefulness of calgranulin B as a stool marker for colorectal cancer in a pilot study of patients with colorectal cancer.
Methods
We performed 2-DE-based proteomics to screen stool markers for colorectal cancer. We checked the calgranulin B in stools from 77 colorectal cancer patients and from 75 controls by western blot and enzyme-linked immunosorbent assay. We measured calgranulin A using the same methods, and stool hemoglobin by immunologic fecal occult blood test.
Results
Fecal calgranulin A did not show any difference, but stool calgranulin B of colorectal cancer patients was significantly higher than controls [50.6 ng/mg stool protein (SD, 34.8) vs. 20.2 ng/mg stool protein (SD,24.0), respectively, P < 0.001). At the cut off level 24.4 ng/mg stool protein, the sensitivity was somewhat higher than fecal occult blood test (72.0 percent vs. 62.3 percent) but the specificity was much lower than fecal occult blood test (77.1 percent vs. 98.7 percent).
Conclusions
Calgranulin B was increased in stools of colorectal cancer patients but our results suggest that colorectal cancer screening by determination of stool calgranulin B would not be better than conventional fecal occult blood test.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005;5:199–209.
Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–67.
Rhodes JM. Colorectal cancer screening in the UK: Joint Position Statement by the British Society of Gastroenterology, The Royal College of Physicians, and The Association of Coloproctology of Great Britain and Ireland. Gut 2000;46:746–8.
Kronborg O, Ugstad M, Fuglerud P, et al. Fecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 2000;46:795–800.
Brydon WG, Campbell SS, Anderson NA, et al. Fecal calprotectin levels and colorectal neoplasia. Gut 2001;48:579–80.
Shitrit AB, Braverman D, Stankiewics H, et al. Fecal calprotectin as a predictor of abnormal colonic histology. Dis Colon Rectum 2007;50:2188–93.
Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag, 2002.
Shin YK, Yoo BC, Chang HJ, et al. Down-regulation of mitochondrial F1F0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005;65:3162–70.
Ahlquist DA, Gilbert JA. Stool markers for colorectal cancer screening: future considerations. Dig Dis 1996;14:132–44.
Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology 2005;128:192–206.
Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793–8.
Dubrow R, Kim CS, Eldred AK. Fecal lysozyme: an unreliable marker for colorectal cancer. Am J Gastroenterol 1992;87:617–21.
Dubrow R, Yannielli L. Fecal protein markers of colorectal cancer. Am J Gastroenterol 1992;87:854–8.
Nakayama T, Yasuoka H, Kishino T, et al. ELISA for occult fecal albumin. Lancet 1987;1:1368–9.
Roseth AG, Kristinsson J, Fagerhol MK, et al. Fecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 1993;28:1073–6.
Aadland E, Fagerhol MK. Fecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:823–5.
Ton H, Brandsnes Ø, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta 2000;292:41–54.
Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr 2005;40:450–5.
Kristinsson J, Armbruster CH, Ugstad M, et al. Fecal excretion of calprotectin in colorectal cancer: relationship to tumor characteristics. Scand J Gastroenterol 2001;36:202–7.
Summerton CB, Longlands MG, Wiener K, Shreeve DR. Fecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol 2002;14:841–5.
Limburg PJ, Devens ME, Harrington JJ, et al. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. Am J Gastroenterol 2003;98:2299–305.
Hoff G, Grotmol T, Thiis-Evensen E, et al. Testing for fecal calprotectin (PhiCal) in the Norwegian colorectal cancer prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 2004;53:1329–33.
Newton RA, Hogg N. The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils. J Immunol 1998;160:1427–35.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by research grants 0710670–1 (Yoo BC) and 0410063–3 (Lim SB) from the National Cancer Center, Korea.
About this article
Cite this article
Yoo, B.C., Shin, YK., Lim, SB. et al. Evaluation of Calgranulin B in Stools from the Patients with Colorectal Cancer. Dis Colon Rectum 51, 1703–1709 (2008). https://doi.org/10.1007/s10350-008-9381-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10350-008-9381-6